AstraZeneca Drug ‘Approaching The Point Of Diminishing Returns’

After a heart attack (myocardial infarction or MI) patients remain at high risk for recurrent events. The precise role of blood thinning with dual antiplatelet therapy to lower this risk has been the subject of considerable disagreement.  Now a new study offers fresh evidence that one important strategy, prolonged dual antiplatelet therapy, can lower risk over a long period ;but only at the cost of more bleeding complications.

Click here to read the full post on Forbes.

 

 

 

Leave a Reply

%d bloggers like this: